4-bromo-N-[1-(4-methylphenyl)ethylideneamino]aniline | 380309-46-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-N-[1-(4-methylphenyl)ethylideneamino]aniline
• CAS: 380309-46-6
• 化学式: C₁₅H₁₅BrN₂
• 分子量: 303.201
• InChiKey: YBIGCACURGETTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-N-[1-(4-methylphenyl)ethylideneamino]aniline 在 sodium acetate 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 1.25h， 生成 2-{{[1-(4-bromophenyl)-3-(4-methylphenyl)-1H-pyrazol-4-yl]methylene}hydrazono}-3-phenylthiazolidin-4-one
  参考文献：
  名称：

  New heterocyclic hybrids of pyrazole and its bioisosteres: Design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents

  摘要：

  A new series of pyrazole derivatives were synthesized by hybridization with five-membered heterocyclic moieties such as thiazoles, thiazolidinones, 1,3,4-thiadiazoles and pyrazolines. The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum. Compounds 2c, 2d, 4b, 4c, 4d, 5a, 6c, 8c and 9b had more than 90% parasite suppression activity of that found with the antimalarial reference standard drug, chloroquine phosphate and had lower IC50 values than chloroquine. Compounds 4b and 9b were the most active derivatives, and their activities were 5-fold higher than chloroquine. All the newly synthesized compounds were evaluated for their in vitro antileishmanial activity against Leishmania aethiopica promastigotes and amastigote. The results showed that compounds 2c, 2d, 3d, 4b, 4c, 4d and 5a had lower or similar IC50 values than the reference standard drugs, amphotericin B and miltefosine. Compound 3d had the highest antileishmanial activity. Collectively, compounds 2c, 2d, 4b, 4c, 4d and 5a exhibited dual activity against malaria and leishmaniasis and were safe and well tolerated by the experimental animals orally up to 300 mg/kg and parenterally up to 100 mg/kg. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.02.038
• 作为产物：
  描述：

  4-溴苯肼盐酸盐 、 对甲基苯乙酮 在 sodium acetate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 4-bromo-N-[1-(4-methylphenyl)ethylideneamino]aniline
  参考文献：
  名称：

  New heterocyclic hybrids of pyrazole and its bioisosteres: Design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents

  摘要：

  A new series of pyrazole derivatives were synthesized by hybridization with five-membered heterocyclic moieties such as thiazoles, thiazolidinones, 1,3,4-thiadiazoles and pyrazolines. The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum. Compounds 2c, 2d, 4b, 4c, 4d, 5a, 6c, 8c and 9b had more than 90% parasite suppression activity of that found with the antimalarial reference standard drug, chloroquine phosphate and had lower IC50 values than chloroquine. Compounds 4b and 9b were the most active derivatives, and their activities were 5-fold higher than chloroquine. All the newly synthesized compounds were evaluated for their in vitro antileishmanial activity against Leishmania aethiopica promastigotes and amastigote. The results showed that compounds 2c, 2d, 3d, 4b, 4c, 4d and 5a had lower or similar IC50 values than the reference standard drugs, amphotericin B and miltefosine. Compound 3d had the highest antileishmanial activity. Collectively, compounds 2c, 2d, 4b, 4c, 4d and 5a exhibited dual activity against malaria and leishmaniasis and were safe and well tolerated by the experimental animals orally up to 300 mg/kg and parenterally up to 100 mg/kg. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.02.038

文献信息

• Design and synthesis of novel quinazolinone-pyrazole derivatives as potential α-glucosidase inhibitors: Structure-activity relationship, molecular modeling and kinetic study
  作者：Fateme Azimi、Homa Azizian、Mohammad Najafi、Farshid Hassanzadeh、Hojjat Sadeghi-aliabadi、Jahan B. Ghasemi、Mohammad Ali Faramarzi、Somayeh Mojtabavi、Bagher Larijani、Lotfollah Saghaei、Mohammad Mahdavi

  DOI：10.1016/j.bioorg.2021.105127

  日期：2021.9

  structure–activity relationship suggested that the variation in the inhibitory activities of the compounds affected by different substitutions on phenyl rings of diphenyl pyrazole moiety. The enzyme kinetic studies of the most potent compound 9i revealed that it inhibited α-glucosidase in a competitive mode with a Ki of 56 μM. Molecular docking study was performed to predict the putative binding interaction. As expected

  在这项研究中，设计、合成了一系列新的喹唑啉酮-吡唑杂化物，并筛选了它们的 α-葡萄糖苷酶抑制活性。的结果在体外筛选表明所有分子杂交显示出更多的抑制活性（IC 50值从60.5±0.3μM-186.6±20μM范围）相比于标准阿卡波糖（IC 50 = 750.0 ± 10.0 µM）。有限的构效关系表明化合物抑制活性的变化受二苯基吡唑部分苯环上不同取代的影响。最有效的化合物 9i 的酶动力学研究表明，它以竞争模式抑制 α-葡萄糖苷酶，Ki 为 56 μM。进行分子对接研究以预测假定的结合相互作用。正如预期的那样，初始结构设计中使用的所有药效基团在与酶结合位点的相互作用中都发挥着关键作用。此外，通过进行分子动力学研究和 MM-GBSA 计算，
• Prakash, Om; Pundeer, Rashmi; Ranjan, Pooja, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 4, p. 563 - 568
  作者：Prakash, Om、Pundeer, Rashmi、Ranjan, Pooja、Pannu, Kamaljeet、Dhingra, Yogita、Aneja

  DOI：——

  日期：——
• New heterocyclic hybrids of pyrazole and its bioisosteres: Design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents
  作者：Adnan A. Bekhit、Ahmed M.M. Hassan、Heba A. Abd El Razik、Mostafa M.M. El-Miligy、Eman J. El-Agroudy、Alaa El-Din A. Bekhit

  DOI：10.1016/j.ejmech.2015.02.038

  日期：2015.4

  A new series of pyrazole derivatives were synthesized by hybridization with five-membered heterocyclic moieties such as thiazoles, thiazolidinones, 1,3,4-thiadiazoles and pyrazolines. The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum. Compounds 2c, 2d, 4b, 4c, 4d, 5a, 6c, 8c and 9b had more than 90% parasite suppression activity of that found with the antimalarial reference standard drug, chloroquine phosphate and had lower IC50 values than chloroquine. Compounds 4b and 9b were the most active derivatives, and their activities were 5-fold higher than chloroquine. All the newly synthesized compounds were evaluated for their in vitro antileishmanial activity against Leishmania aethiopica promastigotes and amastigote. The results showed that compounds 2c, 2d, 3d, 4b, 4c, 4d and 5a had lower or similar IC50 values than the reference standard drugs, amphotericin B and miltefosine. Compound 3d had the highest antileishmanial activity. Collectively, compounds 2c, 2d, 4b, 4c, 4d and 5a exhibited dual activity against malaria and leishmaniasis and were safe and well tolerated by the experimental animals orally up to 300 mg/kg and parenterally up to 100 mg/kg. (C) 2015 Elsevier Masson SAS. All rights reserved.